Grifols (GRFS) Projected to Post Quarterly Earnings on Tuesday

Grifols (NASDAQ:GRFS - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect Grifols to post earnings of $0.22 per share and revenue of $1.92 billion for the quarter.

Grifols Stock Up 1.7%

Shares of GRFS traded up $0.17 during mid-day trading on Thursday, hitting $10.02. The company's stock had a trading volume of 376,900 shares, compared to its average volume of 952,600. The company's 50-day moving average is $8.81 and its 200-day moving average is $7.87. Grifols has a 52-week low of $6.19 and a 52-week high of $10.30. The firm has a market capitalization of $6.89 billion, a price-to-earnings ratio of 8.57, a PEG ratio of 0.36 and a beta of 0.55. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GRFS. JPMorgan Chase & Co. upped their price target on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in shares of Grifols by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company's stock worth $29,948,000 after acquiring an additional 80,507 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Grifols by 21.7% during the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company's stock worth $3,461,000 after acquiring an additional 86,768 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Grifols during the 1st quarter worth approximately $184,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.